John W. Baddley
Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Dr. John W. Baddley

Infectious Disease
Johns Hopkins University
600 N Wolfe St, Blalock 266, 
Baltimore, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
26 Years of Experience
Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Johns Hopkins University
600 N Wolfe St, Blalock 266, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Baddley is an Infectious Disease provider in Baltimore, Maryland. Dr. Baddley has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Cryptococcosis, Shingles, Sepsis, and Febrile Neutropenia. Dr. Baddley is currently accepting new patients.

His clinical research consists of co-authoring 178 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Methicillin-Resistant Staphylococcus Aureus (MRSA).

Specialties
Infectious Disease
Licenses
Internal Medicine in AL
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287
Other Locations
JOHNS HOPKINS UNIVERSITY
5601 Lloch Raven Blvd, Baltimore, MD 21239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Enrollment Status: Recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: DAS181
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Enrollment Status: Completed
Publish Date: January 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

178 Total Publications

Increased Rate of Deceased Donor Liver Transplantation for Candidates Willing to Receive Organs from Donors With HIV.
Increased Rate of Deceased Donor Liver Transplantation for Candidates Willing to Receive Organs from Donors With HIV.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: July 07, 2025
Similar Doctors
Eli N. Perencevich
Elite in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Eli N. Perencevich
Infectious Disease
Elite in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Eli N. Perencevich
Infectious Disease
22 S Greene St, 
Baltimore, MD 
 (1.9 miles away)
410-328-5793
Languages Spoken:
English
See accepted insurances

Eli Perencevich is an Infectious Disease provider in Baltimore, Maryland. Dr. Perencevich is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Pneumonia, and Severe Acute Respiratory Syndrome (SARS).

Sara E. Cosgrove
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Sara E. Cosgrove
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Sara E. Cosgrove
Infectious Disease
600 N Wolfe St, 
Baltimore, MD 
 (0.1 miles away)
410-955-1725
Languages Spoken:
English
See accepted insurances

Sara Cosgrove is an Infectious Disease provider in Baltimore, Maryland. Dr. Cosgrove is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). Her top areas of expertise are Sepsis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Pneumonia, and Pseudomonas Stutzeri Infections.

Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Aaron M. Milstone
Pediatric Infectious Disease | Infectious Disease | Pediatrics
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Aaron M. Milstone
Pediatric Infectious Disease | Infectious Disease | Pediatrics

Johns Hopkins University

200 N Wolfe St, 
Baltimore, MD 
 (0.2 miles away)
410-614-3917
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Milstone is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Baltimore, Maryland. Dr. Milstone is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Sepsis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Severe Acute Respiratory Syndrome (SARS), and Neonatal Sepsis. Dr. Milstone is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baddley's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile